GlaxoSmithKline
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Co-administration of Pneumococcal Conjugate Vaccine With DTPa-IPV-Hib Versus Co-administration With DTPa-HBV-IPV/Hib
- Conditions
- Infections, Streptococcal
- Interventions
- Biological: GSK Biologicals´ Pneumococcal Conjugate Vaccine GSK1024850A (Synflorix™)Biological: Pediacel™Biological: Infanrix™ hexa.Biological: Prevenar™
- First Posted Date
- 2008-04-04
- Last Posted Date
- 2019-06-26
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 780
- Registration Number
- NCT00652951
- Locations
- 🇳🇱
GSK Investigational Site, Hoofddorp, Netherlands
Effectiveness of Rotarix™ Against Rotavirus Severe Gastroenteritis (RV SGE) in Infants in Panama
- Conditions
- Infections, Rotavirus
- Interventions
- Other: No intervention
- First Posted Date
- 2008-04-04
- Last Posted Date
- 2017-09-05
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 885
- Registration Number
- NCT00653198
- Locations
- 🇵🇦
GSK Investigational Site, Panama, Panama
Immunogenicity of GSK Biologicals' Pandemic Influenza Vaccine (GSK1562902A) at Different Boosting Vaccination Schedules
- Conditions
- Influenza
- Interventions
- Biological: Pandemic influenza vaccine GSK1562902A
- First Posted Date
- 2008-04-04
- Last Posted Date
- 2018-08-02
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 845
- Registration Number
- NCT00652743
- Locations
- 🇹🇭
GSK Investigational Site, Bangkok, Thailand
A Study to Evaluate the Effects of GW679769 on Sleep and Cognitive Function in Subjects With Primary Insomnia
- Conditions
- Sleep Initiation and Maintenance Disorders
- First Posted Date
- 2008-04-02
- Last Posted Date
- 2017-08-08
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 48
- Registration Number
- NCT00650871
- Locations
- 🇺🇸
GSK Investigational Site, Philadelphia, Pennsylvania, United States
A Single Dose Bioequivalence Study OfTwo Formulations Of Nicotine Lozenges
- Conditions
- Healthy Volunteer Smokers
- Interventions
- Drug: 4 mg nicotine lozengeDrug: 2 mg nicotine prototypeDrug: 4 mg nicotine prototypeDrug: 2 mg nicotine lozenge
- First Posted Date
- 2008-04-02
- Last Posted Date
- 2014-11-24
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 32
- Registration Number
- NCT00651352
To Estimate Relative Bioavailability of 5 Formulations of Ronacaleret Given to Healthy Postmenopausal Females
- Conditions
- Osteoporosis
- First Posted Date
- 2008-04-02
- Last Posted Date
- 2016-05-02
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 32
- Registration Number
- NCT00651534
- Locations
- 🇺🇸
GSK Investigational Site, Port Orange, Florida, United States
GSK1247303 First Time in Human Study
- Conditions
- Healthy Subjects
- First Posted Date
- 2008-04-02
- Last Posted Date
- 2010-10-19
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 58
- Registration Number
- NCT00651079
- Locations
- 🇺🇸
GSK Investigational Site, Overland Park, Kansas, United States
Study To Examine The Effects Of Lapatinib On The Pharmacokinetics Of Digoxin In Subjects w/ ErbB2 Positive Breast Cancer
- First Posted Date
- 2008-04-02
- Last Posted Date
- 2017-11-17
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 17
- Registration Number
- NCT00650910
- Locations
- 🇰🇷
GSK Investigational Site, Seoul, Korea, Republic of
Cardiovascular (CV) Risk Evaluation In Type 2 Diabetes Subjects
- Conditions
- Type 2 Diabetes MellitusCV Risk
- First Posted Date
- 2008-04-01
- Last Posted Date
- 2008-10-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1100
- Registration Number
- NCT00648284
Long-term Extension Study Evaluating Extended Release Ropinirole XL (Formerly Referred to as Ropinirole CR) in Patients Who Already Completed Either Study 167 or 164
- First Posted Date
- 2008-04-01
- Last Posted Date
- 2013-05-06
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 76
- Registration Number
- NCT00650104
- Locations
- 🇺🇸
GSK Investigational Site, Houston, Texas, United States